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Abstract
Trisomy 21 (Ts21) affects craniofacial precursors in individuals with Down syndrome (DS). The resultant craniofacial features
in all individuals with Ts21 may significantly affect breathing, eating and speaking. Using mouse models of DS, we have
traced the origin of DS-associated craniofacial abnormalities to deficiencies in neural crest cell (NCC) craniofacial precursors
early in development. Hypothetically, three copies of Dyrk1a (dual-specificity tyrosine-(Y)-phosphorylation regulated kinase
1A), a trisomic gene found in most humans with DS andmouse models of DS, may significantly affect craniofacial structure.
We hypothesized that we could improve DS-related craniofacial abnormalities in mouse models using a Dyrk1a inhibitor or
by normalizing Dyrk1a gene dosage. In vitro and in vivo treatment with Epigallocatechin-3-gallate (EGCG), a Dyrk1a inhibitor,
modulated trisomic NCC deficiencies at embryonic time points. Furthermore, prenatal EGCG treatment normalized some
craniofacial phenotypes, including cranial vault in adult Ts65Dnmice. Normalization of Dyrk1a copy number in an otherwise
trisomic Ts65Dnmice normalized many dimensions of the cranial vault, but did not correct all craniofacial anatomy. These
data underscore the complexity of the gene–phenotype relationship in trisomy and suggest that changes in Dyrk1a expres-
sion play an important role in morphogenesis and growth of the cranial vault. These results suggest that a temporally specific
prenatal therapy may be an effective way to ameliorate some craniofacial anatomical changes associated with DS.
Introduction
Down syndrome (DS, OMIM 190685) affects 140 of 100 000 live
births, and all humans with DS exhibit dysmorphic craniofacial
phenotypes and impaired cognition. During prenatal mor-
phogenesis and growth, individuals with Trisomy 21 (Ts21) de-
velop craniofacial abnormalities including reduced maxillary
length, altered frontomaxillary facial angles and short, broad
heads (1–4). These developmental craniofacial differences pref-
ace those seen in newborn, children and adult humans with DS
including midface hypoplasia, a small oral cavity, brachyceph-
aly and a generalized reduction in facial dimensions due to
decreased growth rates and increased fluctuating asymmetry
of facial soft tissues associated with decreased developmen-
tal homeostasis (4–8). Ts21 results in altered craniofacial
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morphogenesis and growth that may impact orofacial structure
or function, potentially resulting in eating, breathing and
speech impairments (9–11).
Ts65Dn mice are the most widely used model of DS, have
three copies of orthologs to 50% of the genes on human chro-
mosome 21 (Hsa21) and exhibit phenotypes associated with DS
including craniofacial dysmorphology, skeletal alterations and
cognitive deficits (7,12,13). Newborn Ts65Dn mice exhibit re-
duced dimensions along the rostrocaudal and mediolateral axes
of the face and palate, anterior and posterior neurocranium,
and mandible (14). Adult Ts65Dn mice exhibit increased neuro-
cranial widths (i.e. brachycephaly), a flattened occiput and an
overall reduction in size of much of the craniofacial skeleton;
including the midface, maxilla, mandible, facial height and
interorbital breadth (7).
Neural crest cells (NCC) are an important component of cra-
niofacial development and contribute to the majority of the
bone, cartilage, connective tissue and peripheral nervous tissue
in the craniofacial complex (15–17). Using the Ts65Dn DS mouse
model, we provided the first experimental evidence that tri-
somy disrupts NCC that would lead to the craniofacial abnor-
malities associated with DS (18). We found that the trisomic
mandibular precursor, or first pharyngeal arch (PA1), was
smaller in size and had fewer NCC by embryonic day 9.5 (E9.5).
Additional deficits were quantified in trisomic embryonic cra-
nial NCC generation, migration and proliferation (18). In later
development, Ts65Dn mice also displayed a smaller mandibular
precursor than normal E13.5 embryos (19). These and other de-
velopmental changes result in modified craniofacial structures
in newborn and adult Ts65Dn mice that are similar to those
found in humans with DS (7,14).
It has been hypothesized that differential expression of
DYRK1A (dual-specificity tyrosine-(Y)-phosphorylation regu-
lated kinase 1A), a gene found in three copies in humans with
Ts21 as well as in Ts65Dn mice, significantly affects many DS
traits including craniofacial and neurological malformations
(20). DYRK1A is a serine–threonine kinase that regulates many
downstream proteins and transcription factors (20,21) and af-
fects cell proliferation, differentiation and survival (22–24).
Transgenic mice with increased dosage of Dyrk1a show develop-
mental delay, motor impairment, learning and memory defi-
ciencies as well as reduced bone mass and altered bone
structure (21,25–28) similar to developmental, cognitive and
morphological phenotypes observed in Ts65Dn mice. We have
shown that eliminating one copy of Dyrk1a in otherwise triso-
mic Ts65Dn mice normalizes the appendicular skeleton (29).
One of the many mechanisms regulated by Dyrk1a via protein
phosphorylation is the nuclear localization and activity of nu-
clear factor of activated t-cells (Nfat) transcription factor.
Dyrk1a may control bone development and homeostasis
through the Nfat pathway (28). Nfat has not been widely studied
in vivo in bone, but Nfatc2/4/ mice exhibit craniofacial abnor-
malities (20), suggesting that the Nfat pathway, in addition to
other pathways, may be involved in the morphogenesis, growth
and maintenance of the craniofacial complex.
Epigallocatechin-3-gallate (EGCG) is a known inhibitor of
Dyrk1a protein kinase activity. Dyrk1a is an excellent drug tar-
get because small molecules like EGCG may attach to the ATP
binding site of the Dyrk1a protein kinase (30). EGCG crosses the
placental and blood/brain barriers (31,32). Treatment with an
EGCG-containing supplement (Mega Green Tea Extract—45%
EGCG, 98% polyphenols) in adulthood transiently improved spa-
tial learning, thigmotaxis and novel object cognitive deficits in
Ts65Dn and Dyrk1a transgenic mice (33) and adult hippocampal
neurogenesis in Dyrk1a transgenic mice. Treatment with a simi-
lar EGCG-containing supplement in humans with DS showed
some transient improvements in episodic and working memory
(33), and with additional cognitive training, improvement of
some secondary cognitive measures of executive functioning and
adaptive behavior in functional academic skills (34). We have
used a pure EGCG treatment for 3 weeks in adolescent mice to
improve appendicular bone mineral density and trabecular skele-
tal phenotypes in Ts65Dn DS mice (29). A perinatal pure EGCG
treatment transiently improved hippocampal neurogenesis (35).
Yet, the aforementioned therapies with EGCG or EGCG-containing
supplements are not likely to produce a permanent change in ei-
ther cellular structure of the brain or cognitive function.
Conversely, EGCG treatment during development and maturation
of critical cellular and organ systems has the potential to induce
permanent changes in adult mice or humans.
We hypothesized that increased Dyrk1a activity during em-
bryonic trisomic development, through interactive effects in-
cluding changes in Nfat nuclear localization, significantly
contributes to DS craniofacial dysmorphology in Ts65Dn mice
and individuals with Ts21. By altering Dyrk1a expression, either
by inhibiting activity or by lowering gene dosage during embry-
onic development, we hypothesized that craniofacial skeletal
dysmorphology would be permanently improved in the Ts65Dn
DS mouse model. Our work delineating the time and tissue spe-
cificity of the NCC deficit related to DS led us to propose that
prenatal treatment with EGCG during embryonic stages, when
trisomy disrupts the NCC population, would result in improved
craniofacial structure in both embryonic and adult stages and
may correct gene expression changes caused by trisomy. We
further hypothesized that elimination of one copy of Dyrk1a in
an otherwise trisomic animal would result in improved cranio-
facial anatomy in Ts65Dn mice. We report herein the effect of
EGCG treatment and reduction of Dyrk1a copy number on the
trisomic craniofacial phenotypes associated with DS.
Results
Expression of Dyrk1a and Rcan1 RNA is dysregulated in
the Ts65Dn E9.25 and E9.5 PA1 and neural tube
Dysregulation of Dyrk1a and Regulator of Calcineurin 1 (Rcan1)
have been hypothesized to influence craniofacial phenotypes
associated with DS (20), and we hypothesized that these triso-
mic genes may be involved in the NCC deficit of E9.5 Ts65Dn
embryos (18). Before the NCC deficit is established in trisomic
embryos at E9.25 (15–19 somites), trisomic embryos displayed
decreased expression of Dyrk1a RNA (relative Ts65Dn to euploid
expression) and increased Rcan1 RNA expression in both the
E9.25 PA1 and neural tube (NT) (Fig. 1A). At E9.5 (21–24 somites),
when the NCC deficit is apparent, Dyrk1a RNA expression was
upregulated and Rcan1 RNA expression was downregulated in
the E9.5 PA1 and NT (Fig. 1B).
Nfat localization not altered in E9.5 or E13.5 PA1
To determine the effects of increased copy number of Dyrk1a and
Rcan1 on the cellular localization of Nfatc1 protein in trisomic cra-
niofacial precursors, we conducted immunohistochemistry on
the PA1 of E9.5 and E13.5 Ts65Dn and euploid embryo sections.
Ts65Dn embryos exhibited a similar amount of nuclear Nfatc1
protein in the PA1 cells when compared with euploid littermates
at E9.5 (Supplementary Material, Fig. S1; P¼ 0.22). These results
suggest that the increased Dyrk1a RNA expression and reduced
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Rcan1 RNA expression in the E9.5 PA1 of Ts65Dn as compared
with euploid embryos do not affect Nfatc1 nuclear localization in
the PA1 cells at this time point. Similar to what was observed in
the E9.5 PA1, no significant differences in Nfatc1 nuclear localiza-
tion were found between the E13.5 mandibular precursor cells of
Ts65Dn and euploid embryos, when we have shown a reduced
expression of Dyrk1a RNA and increased expression of Rcan1 RNA
in the trisomic mandibular precursor (19) (Supplementary
Material, Fig. S2; P¼ 0.37). Nfatc2 is involved in cartilage develop-
ment (36) and may be an alternative pathway contributing to the
Ts65Dn mandibular phenotype. Nuclear localized Nfatc2 protein
was also not significantly different in the E13.5 mandibular pre-
cursor cells between euploid and trisomic embryos (data not
shown). Together these data suggest that trisomic Dyrk1a- and
Rcan1-mediated regulation of the Nfat nuclear protein localiza-
tion in cells of the mandibular precursors is likely not a factor in
the altered development of the Ts65Dn mandibular phenotype at
these two developmental time points.
EGCG ameliorates Ts65Dn PA1 cellular proliferation and
migration deficits in vitro
Due to the aberrant cellular phenotype in the trisomic PA1, we
looked at the biological activity of cells that comprise this structure.
Cells isolated from trisomic E9.5 embryonic PA1 showed signifi-
cantly less proliferation than those from euploid PA1 in vitro (Fig. 2).
Treatment of E9.5 PA1 cells with 10 mM EGCG in vitro led to not only
a significant increase in proliferation of trisomic cells from the PA1
but also a significant decrease in the proliferation of trisomic cells
from the NT. Treatment with 25 mM EGCG was sufficient to amelio-
rate the trisomic E9.5 PA1 proliferation deficit without altering NT
proliferation significantly. In addition, treatment with 100 mM EGCG
led to significantly higher proliferation in both E9.5 PA1 and NT
cells than those of euploid animals.
Ts65Dn and euploid E9.5 PA1 and NT cellular migration was
assessed using the scratch assay, in conjunction with dimethyl
sulfoxide (DMSO) or EGCG treatment for 4 h. Ts65Dn E9.5 PA1
cells treated with 10 mM EGCG showed a significant increase in
migration (average number of cells entering the open space)
over euploid levels compared with DMSO treatment over the
72 h of the assay (Fig. 3A). This concentration of EGCG treatment
led to an increase in migration of Ts65Dn NT cells that nearly
reached euploid levels after 72 h in culture (Fig. 3B). The ratio of
trisomic to euploid migration of E9.5 PA1 and NT cells was nor-
malized with 10 or 25 mM EGCG treatment (Fig. 3A and B).
Harmine ameliorates Ts65Dn PA1 proliferation
deficits in vitro
Similar to EGCG, harmine binds the ATP-binding pocket of
Dyrk1a and inhibits its activity (37). Harmine was also assessed
Figure 1. Dysregulation of RNA expression from Hsa21 homologous genes found in three copies in Ts65Dn mice occurs in the PA1 and NT early in development. (A)
Dyrk1a RNA expression was significantly downregulated in the E9.25 PA1 and NT of trisomic embryos, whereas Rcan1 RNA expression was significantly upregulated in
both the E9.25 PA1 and NT in trisomic embryos (N¼5 euploid, 5 Ts65Dn PA1; 5 euploid, 5 Ts65Dn NT). (B) Conversely, Dyrk1a RNA expression was upregulated in the
E9.5 PA1 and NT in trisomic embryos relative to euploid littermates, whereas Rcan1 RNA expression was downregulated in these tissues (N¼ 7 euploid, 7 Ts65Dn PA1; 5
euploid, 5 Ts65Dn NT). For statistical analysis, two-tailed Student’s t-tests were performed. Statistical significance is annotated as * for P0.05. Error bars indicate stan-
dard error of the mean.
Figure 2. Ts65Dn PA1 cells displayed a proliferation deficit which can be over-
come with EGCG treatment. Cells from the PA1 of E9.5 Ts65Dn embryos dis-
played impaired proliferation compared with euploid cells (P0.01) (N¼ 8
euploid, 7 Ts65Dn). A significant cellular proliferation occurred with 25 mM EGCG
treatment for 4h (P0.001) (N¼10 euploid, 10 Ts65Dn). Addition of 100 mM EGCG
led to an increase in proliferation above euploid levels (P0.001). Cells derived
from the NT displayed no deficit in proliferation, but were still affected by EGCG
treatment. A dose of 10 mM (N¼10 euploid, 10 Ts65Dn) appeared to adversely af-
fect proliferation of cells from NT (P0.01), whereas 25 mM EGCG produced no
change from untreated trisomic cells (P¼0.89). A significant increase in cells
was seen, however, in cells treated with 100 mM EGCG (N¼10 euploid, 10
Ts65Dn) to above euploid levels (P0.001). For statistical analysis, a two-tailed
Student’s t-test was performed. Statistical significance is annotated as * for
P0.05 and ** for P0.001 with respect to the untreated cells by tissue type.
Error bars indicate standard error of the mean.
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for biological effects in cells from E9.5 Ts65Dn PA1 and NT.
Cellular proliferation in both trisomic and euploid E9.5 PA1 and
NT cells was amplified with increasing concentrations of har-
mine (Supplementary Material, Fig. S3).
In vivo EGCG treatment of Ts65Dn offspring normalizes
some trisomic embryonic structures to euploid levels
Due to the abrogation of trisomic cellular phenotypes upon
EGCG treatment in vitro, Ts65Dn and euploid pregnant females
were treated with EGCG or phosphate buffered saline (PBS) by
oral gavage to determine how EGCG affects embryos in vivo.
Pregnant Ts65Dn or euploid mothers were given PBS or 200mg/
kg EGCG twice daily on gestational days 7 and 8 (E7 and E8).
EGCG treatment did not adversely affect litter size
(Supplementary Material, Fig. S4) or average somite numbers
between embryo genotypes and treatments (Supplementary
Material, Fig. S5), though we did observe increased variability in
somite numbers from mothers receiving EGCG (Supplementary
Material, Fig. S6).
In 21–24 somite E9.5 embryos from mothers receiving
EGCG treatment, trisomic PA1 volume increased significantly
compared with Ts65Dn embryos receiving PBS alone, but not
to the size of the E9.5 euploid embryonic PA1 that received
PBS. Furthermore, euploid E9.5 embryos receiving EGCG
showed a significant increase in PA1 volume compared with
euploid embryos receiving PBS (Fig. 4A). Trisomic E9.5
embryos receiving EGCG showed an increase in NCC number
to near PBS-treated euploid levels (Fig. 4B). Euploid embryos
receiving EGCG also displayed an increase in NCC number
in the PA1 compared with euploid embryos receiving PBS.
E9.5 trisomic embryos receiving PBS were significantly
smaller than euploid embryos receiving PBS, and giving
EGCG to trisomic embryos was not sufficient to change this
relationship (Fig. 4C). However, E9.5 euploid embryos receiv-
ing EGCG displayed a significantly increased total embryo
volume as compared with euploid embryos receiving PBS
(Fig. 4C).
In vivo EGCG treatment alters gene expression in
pathways implicated in trisomic craniofacial
development
Relative RNA expression (to that of untreated euploid
embyros) of Dyrk1a, Rcan1, Shh (sonic hedgehog), Gli1 (glioma-
associated oncogene family zinc finger 1), Ptch1 (patched 1)
and Ets2 (V-ets avian erythroblastosis virus E26 oncogene
homolog 2), all of which have been implicated in DS cranio-
facial development or developmental pathways (20,38,39),
was examined in the PA1 of E9.5 embryos obtained from
mothers receiving EGCG or PBS on E7 and E8. Significant de-
creases in Ptch and Ets2 RNA expression and significant in-
creases in Rcan1 and Shh RNA expression to euploid levels
were observed in the EGCG-treated trisomic PA1 relative to
original trisomic baseline expression values in untreated em-
bryos (Fig. 5).
Elongated treatment of lower dose EGCG has little effect
on trisomic embryos
We hypothesized that treatment of pregnant Ts65Dn mothers
with a lower dose of EGCG from the start of pregnancy to E9.5
might more comprehensively correct the cellular and volumet-
ric deficits of developing trisomic PA1 and embryos to resem-
ble measurements in euploid littermates. When pregnant
Ts65Dn mice were given 0.124 mg/ml EGCG from E0 to E9, fe-
males ingested 12mg/kg/day EGCG (taking into account deg-
radation of EGCG) (40). There was no difference in the amount
of EGCG or water (control) that the pregnant females drank.
There was a significant increase in PA1 volume in euploid E9.5
embryos from trisomic mothers [Eu/(Ts)] compared with
untreated embryos of the same genotype (P¼ 0.046) (Fig. 6A).
This elongated treatment of a lower dosage of EGCG, however,
did not lead to significant improvements in the number of
NCC in the PA1 (Fig. 6B) nor total embryo volume of E9.5
trisomic embryos compared with those treated with water
(Fig. 6C).
Figure 3. Ts65Dn PA1 and NT cells displayed migration deficits at E9.5 which can be overcome with EGCG treatment. (A) Cells from the PA1 of Ts65Dn E9.5 embryos dis-
played an initial cellular migration deficit (average number of cells traveling into the space made by the scratch, P0.001) which was not overcome through the pro-
gression of the scratch assay (N¼11 euploid, 8 Ts65Dn). However, treatment with both 10 mM (P0.01) (N¼8 euploid, 8 Ts65Dn) and 25 mM EGCG (P0.01) (N¼7
euploid, 7 Ts65Dn) was sufficient to rescue this cellular migration deficit within 24h. Migration trends were maintained in the PA1 at 48 and 72h (P0.01 for all condi-
tions). (B) Cellular migration in the NT was deficient at 24h postassay initiation, but appeared to reach euploid levels of migration by the completion of the assay.
Treatment with 10 mM (P0.05) and 25 mM (P0.05) rescued this initial migration deficit by 24h through the termination of the assay. For statistical analysis, two-tailed
Student’s t-tests were performed. Statistical significance is annotated as * for P0.05 and ** for P0.01 with respect to untreated cells by tissue type. Error bars indicate
standard error of the mean.
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Effects of EGCG treatment or Dyrk1a copy number on
postnatal craniofacial structure
We tested whether prenatal EGCG treatment or a reduction in
Dyrk1a dosage would have a permanent effect on postnatal cra-
niofacial structure in trisomic and euploid offspring at 6 weeks of
age. Craniofacial structure from trisomic and euploid offspring
that received EGCG treatment at E7–E8 or offspring from Ts65Dn
Dyrk1aþ/ matings was examined at 6 weeks of age. Using
Euclidian distance matrix analysis (EDMA) (7,41,42), a total of 231
unique linear distance measures were evaluated from eachmouse
skull, and separate two-sample analyses of the cranial vault, facial
skeleton, cranial base and mandible were carried out. EDMA confi-
dence interval tests (a¼ 0.10) revealed morphological patterns of
variation unique to each comparison of mouse samples.
When Ts65Dn and euploid offspring that received PBS from
E7-E8 were compared, differences in the percentage of significant
linear distances were notable in the cranial base, cranial face,
mandible and cranial vault (Table 1). The great majority of sig-
nificant differences across the craniofacial complex was larger
in euploid as compared with Ts65Dn mice (Fig. 7A). When
Ts65DnþEGCG were compared with euploidþPBS mice, a re-
duced percentage of significant differences was most notable in
the cranial vault as compared with the previous comparison. The
great majority of significant differences was larger in the euploid
compared with the Ts65DnþEGCGmice; however, differences lo-
calized to the anterior cranial vault and zygomatic bones were
smaller in the euploid relative to the Ts65DnþEGCG mice
(Fig. 7B). Very few differences were seen when Ts65Dn mice that
received EGCG were compared with Ts65Dn mice that received
PBS (Fig. 7C). The most significant differences were seen across
all dimensions of craniofacial regions when euploidþ EGCG were
compared with euploidþPBS mice (Table 1). The great majority
of significant differences was larger in the euploidþEGCG mice
as compared with euploidþ PBS mice; however, four measures
localized to the anterior and posterior cranial vault including
mediolateral measures of the frontal and zygomatic bones and
an anterioposterior measure of the interparietal bone were signif-
icantly smaller in the euploidþEGCG relative to euploidþ PBS
mice (Fig. 7D).
Fewer significant differences were seen when one copy of
Dyrk1a was removed from otherwise trisomic Ts65Dn mice
(Ts65Dn,Dyrk1aþ/—two copies of Dyrk1a) or euploid mice
(euploid,Dyrk1aþ/—one copy of Dyrk1a) (Table 1). When euploid
and Ts65Dn mice from a (Ts65Dn  Dyrk1aþ/) mating were
compared, relatively few significant differences were found
across the face, cranial base and mandible, but numerous sig-
nificant difference occurred across the cranial vault (Table 1 and
Fig. 7E). Unexpectedly, almost all significant differences were
smaller in the euploid as compared with Ts65Dn mice. No sig-
nificant differences were seen in the cranial base, and few fa-
cial, mandibular or cranial vault differences were found when
comparing Ts65Dn,Dyrk1aþ/ and euploid mice (Fig. 7F). In
Ts65Dn,Dyrk1aþ/ mice, differences in the cranial vault were
Figure 4. Effects of EGCG treatment given at E7–E8 on E9.5 PA1 volume, NCC number and embryo volume. (A) Ts65Dn embryos receiving PBS in utero displayed a smaller PA1
volume than euploid embryos receiving PBS (P0.001). Treatment of Ts65Dn embryos with EGCG improved PA1 volume to above baseline trisomic PA1 volume (P 0.001), but
not to PBS-treated euploid PA1 volume. Treatment of euploid embryos with EGCG led to increased PA1 over non-treated euploid PA1 volume (P 0.05). (B) Treatment of triso-
mic embryos with EGCG ameliorated the NCC deficit to euploid levels (P¼ 0.082). Treatment of euploid embryos with EGCG, led to an increase in NCC above euploid levels
(P0.05). (C). Treatment of trisomic embryos with EGCG did not lead to a significant increase in volume compared euploid embryos, but did increase embryonic volume in
comparison to PBS-treated trisomic embryos. Euploid embryos treated with EGCG displayed increased embryo volume compared with euploid-treated PBS embryos, but this
value was not significant (P¼0.092) (Ts65Dn N¼4, Ts65DnþEGCG N¼ 4, euploid N¼4, euploidþPBS N¼4). For statistical analysis, two-tailed Student’s t-tests were per-
formed. Statistical significance is annotated as ** for P0.001 for untreated trisomic versus euploid, †P0.05 and ††P0.001 for EGCG-treated versus -untreated of the same
genotype, and #P0.05 and ##P0.001 for trisomic EGCG-treated versus euploid-untreated comparisons. Error bars indicate standard error of themean.
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largely corrected (Fig. 7F) as compared with results from the
comparisons of Ts65Dn and euploid mice from a (Ts65Dn 
Dyrk1aþ/) mating (Fig. 7E, Table 1). When Ts65Dn,Dyrk1aþ/
and Ts65Dn mice were compared, one fewer copy of Dyrk1a on
an otherwise trisomic background unexpectedly caused the ma-
jority of significant linear distances to be smaller in the
Ts65Dn,Dyrk1aþ/ relative to the Ts65Dn mice (Fig. 7G). Very few
significant differences were found when euploid (two copies
Dyrk1a) and euploid,Dyrk1aþ/ (one copy Dyrk1a) were compared
(Fig. 7H).
Effects of EGCG treatment or Dyrk1a copy number on
postnatal mass and airway volume
Similar to previous studies (43), Ts65Dn mice had a significantly
smaller mass than euploid 6-week-old littermates when treated
with PBS or when compared with littermates with Dyrk1a copy
number variants (Table 2). Treatment with EGCG significantly
reduced the mass of Ts65Dn and euploid littermates. Consistent
with previous results (29,44), Ts65Dn,Dyrk1aþ/ mice exhibited
significantly increased mass when compared with Ts65Dn lit-
termates, and euploid,Dyrk1aþ/mice were significantly smaller
than euploid littermates. Nasopharyngeal airway volume was
not significantly different between Ts65Dn and euploid mice or
between Ts65Dn and Ts65Dn mice receiving EGCG. There were
no significant differences in nasopharyngeal airway volume
between Ts65Dn and Ts65Dn,Dyrk1aþ/ littermates, but
euploid,Dyrk1aþ/ mice had a significantly smaller nasopharyn-
geal airway volume than euploid mice (Table 2).
Discussion
Expression of Dyrk1a RNA was decreased in the PA1 and NT of
Ts65Dn as compared with euploid embryos at E9.25 but signifi-
cantly increased in the same structures at E9.5. Rcan1 RNA
expression exhibited the opposite effect at these time points.
We have previously shown that Dyrk1a RNA expression was sig-
nificantly decreased and Rcan1 expression increased in the E10
PA1 of Ts65Dn relative to euploid embryos (45) and both Dyrk1a
and Rcan1 exhibited significantly increased RNA expression in
the Ts65Dn as compared with euploid E13.5 mandibular precur-
sor (19). Taken together, these data indicate that expression of
trisomic Dyrk1a and Rcan1 RNA are not consistently increased
or decreased in the mandibular precursor of developing Ts65Dn
embryos. These data may help clarify why reducing Dyrk1a
copy number in Ts65Dn mice throughout development does not
seem to significantly normalize the entire mandibular structure
in 6-week-old Ts65Dn mice. Changes in RNA expression of
Dyrk1a and Rcan1 in trisomic embryos appear to be temporally
specific in the developing mandible. Furthermore, the dysregu-
lation of Dyrk1a and Rcan1, both hypothesized to be linked to al-
tered Nfatc expression in trisomic animals (20), do not seem to
affect Nfatc nuclear localization in mandibular precursor cells
at either E9.5 or E13.5. It may be that Nfatc cellular localization
or expression is dysregulated at other time points during man-
dibular development or not altered by trisomic genes. We have
previously shown that Nfatc nuclear localization is not altered
in trisomic bone development at the time of the cartilage anla-
gen (E13.5) (46).
This study shows that a temporally specific prenatal EGCG
treatment improves some craniofacial dysmorphology associ-
ated with DS in Ts65Dn embryos and mice. EGCG and harmine,
both inhibitors of Dyrk1a activity (47), effectively improve NCC-
related deficits in proliferation and migration in vitro in PA1 cells
from Ts65Dn E9.5 embryos. In vivo treatment with EGCG at E7
and E8, around the time of the developing NCC deficit, appears
to improve some of the NCC embryonic dysmorphology, espe-
cially in PA1 volume and NCC number in Ts65Dn E9.5 embryos.
Gene expression was also altered by EGCG treatment and essen-
tially normalized Rcan1, Shh, Ptch1 and Ets2 RNA expression—all
of which are genes hypothesized to be related to some DS cra-
niofacial deficits (18,38,39,48). EGCG treatment and Dyrk1a ac-
tivity have been shown to be connected to and modulate the
Shh pathway (49–51). However, a longer lasting EGCG treatment
at a lower dose (E0–E9) did not have the same corrective effect
on the trisomic embryonic structure at E9.5. These results sug-
gest that timing and dosage of EGCG treatment are important in
treating DS-related phenotypes.
The embryonic changes caused by prenatal EGCG treatment
at E7–E8 appear to improve some craniofacial structures, particu-
larly the cranial vault, in adult trisomic mice. The morphometric
analysis used in this study (i.e. EDMA) assessed local form differ-
ences by comparing all unique linear measures across the cra-
nial vault, face, base and mandible. Because of the potential for a
large number of linearmeasures to significantly differ, it is useful
to consider patterns of significant differences across craniofacial
structures and to calculate summary statistics based on signifi-
cant results. Here, we counted the number of significant linear
distances in a particular region and divided this value by the to-
tal number of unique linear distances for that particular region
(i.e. the number of linear distances that could have potentially
been significantly different) to determine the percentage of sig-
nificant differences for each craniofacial region (Table 1). This
summary statistic is useful for comparing global results on a re-
gion by region basis from multiple two-sample EDMA analyses
(4,52), although specific dimensions of interest for each region
should be explored using local results (Fig. 7). EGCG treatment of
Ts65Dn embryos reduced the percentage of significant differ-
ences from 19% to 14% in the cranial base, from 32% to 26% in
Figure 5. EGCG exposure leads to alterations of RNA expression from genes in-
volved in pathways impacting craniofacial development E9.5 PA1. Baseline ex-
pression of RNA encoded by Dyrk1a, Rcan1, Shh, Gli1, Ptch1 and Ets2 quantified as
cDNA by qRT-PCR revealed alterations in expression from euploid values (equiv-
alent to a relative expression value of 1). RNA expression from these genes was
altered in several cases in E9.5 trisomic PA1 receiving EGCG treatment in utero
with most achieving near euploid values of relative expression. For statistical
analysis, two-tailed Student’s t-tests were performed. Statistical significance is
annotated as * for P0.05 for Ts65Dnþ PBS versus Ts65DnþEGCG, †P0.05 for
Ts65DnþPBS untreated versus euploidþEGCG and #P0.05 for Ts65DnþEGCG
versus euploidþEGCG. Error bars indicate standard error of the mean.
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the face and from 22% to 5% in the cranial vault in adult mice.
This suggests that EGCG treatment slightly normalized cranial
base and face morphology and considerably improved cranial
vault morphology. In contrast to the results from our embryonic
study, EGCG treatment did not significantly improve the overall
mandibular dysmorphology in 6-week trisomic animals. It may
be that prenatal treatment with EGCG has a larger effect on triso-
mic NCC precursors that are components of other parts of the
craniofacial skeleton and therefore developmentally integrated,
whereas the mandible is developmentally modular and therefore
less affected by treatments influencing development of other
craniofacial structures such as the cranial vault, face and base.
Overall the results imply that EGCG treatment at E7–E8 improves
some craniofacial morphology in Ts65Dn mice, especially for the
cranial vault, but does not entirely correct craniofacial structural
abnormalities attributed to trisomy.
Normalization of Dyrk1a to two copies in otherwise trisomic
Ts65Dnmice did not fully correct craniofacial dysmorphology as-
sociated with DS. Yet, our data indicate that trisomic Dyrk1amay
be important for morphogenetic events that give rise to the shape
and size of the cranial vault. Comparisons of euploid mice with
Ts65Dn (three copies Dyrk1a) and Ts65Dn,Dyrk1aþ/ (two copies
Dyrk1a) (Table 1 and Fig. 7E and F) unexpectedly revealed numer-
ous smaller dimensions in euploid cranial vaults relative to
Ts65Dn mice, but removal of one copy of Dyrk1a in Ts65Dn mice
improved cranial vault morphology as evidenced by the reduc-
tion in significant cranial vault differences shown in Figure 7F rel-
ative to Figure 7E. The comparison of Ts65Dn,Dyrk1aþ/ and
Ts65Dn mice (Fig. 7G) yielded numerous significant cranial vault
differences, but significant differences were smaller in Ts65Dn
mice with only two copies of Dyrk1a. Furthermore, EGCG treat-
ment at E7 and E8 corrected a large number of significant differ-
ences in the cranial vault of 6-week-old Ts65Dn mice as
compared with euploid littermates given PBS (Table 1 and Fig. 7A
and B). In agreement with these results, we previously found that
trisomic Dyrk1a has a major influence on the appendicular
skeleton, and that reduction of Dyrk1a copy number in
Ts65Dn,Dyrk1aþ/ mice did not restore bone mineral density in
the skull and mandible to euploid levels (29). Additionally, both
of the airways of Ts65Dn and euploid mice from (Ts65Dn 
Dyrk1aþ/) matings not carrying the null Dyrk1a allele were larger
in magnitude in comparison with those mice with EGCG/PBS
treatment. Taken together, these results underscore the com-
plexity of the gene–phenotype analyses, and suggest that
changes in trisomic Dyrk1a expression, either via EGCG treatment
or copy number reduction, play an important role in morphogen-
esis and growth of the cranial vault, and perhaps to a lesser de-
gree, other craniofacial structures. It seems likely that major
primary changes in cranial vault morphogenesis and growth
could produce minor changes in the face, cranial base and man-
dible through complex regulatory and pleiotropic interactions
and integrated functional craniofacial requirements related to or-
gan protection and mastication, but additional investigations are
necessary to verify this hypothesis. A limitation of our study is
that we have not shown how EGCG treatment affects Dyrk1a ac-
tivity in craniofacial precursors or adult structures.
Figure 6. Effects of EGCG treatment given at E0–E9.5 on E9.5 PA1 volume, NCC number and embryo volume. Ts/(Ts), trisomic embryos from Ts65Dn mothers; Eu/(Ts),
euploid embryos from Ts65Dn mothers; Eu/(Eu), euploid embryos from euploid B6C3F1 mothers. Ts/(Ts) þ H20: n¼9; Ts/(Ts) þ EGCG: N¼5; Eu/(Ts) þ H20: N¼6; Eu/(Ts)
þ EGCG: N¼9; Eu/(Eu) þ H20: N¼8; Eu/(Eu) þ EGCG: N¼ 7. (A) No significant differences were seen in the PA1 volume of EGCG-treated trisomic Ts/(Ts) or euploid Eu/
(Eu) embryos compared with untreated embryos (P¼0.058). PA1 volume was significantly increased in EGCG-treated euploid embryos [Eu/(Ts)] compared with
untreated embryos [Eu/(Ts)]. (B) EGCG treatment from E0 to E9.5 at 12mg/kg/day did not significantly alter the number of NCC in any treatment groups compared
with untreated embryos. The slight but non-significant decrease in NCC in EGCG-treated Ts/(Ts) embryos was likely due to a lower average somite number in this
group compared with water treated embryos (P¼0.0613). (C) No differences were found between treated and untreated embryo volume of any trisomic or euploid em-
bryos. Statistical significance is annotated as * for P 0.05. Error bars indicate standard error of the mean.
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Differences in craniofacial and airway measurements be-
tween trisomic and euploid mice from the pharmacological and
genetic alterations were not expected. Ts65Dn and euploid mice
from either control (PBS) treatment or that did not carry the
Dyrk1a null allele exhibited similar overall weights at 6 weeks of
age (Table 2). Yet, the craniofacial measurements in trisomic
offspring (without a null Dyrk1a gene) from (Ts65Dn 
Dyrk1aþ/) matings were generally larger than euploid litter-
mates (Fig. 7E and F). To generate the Dyrk1aþ/ mice used in
the breeding scheme of this study, C57BL/6-129/Ola-mixed ge-
netic background Dyrk1aþ/ mice carrying the null Dyrk1a allele
(44,53) were bred onto a B6C3 advanced intercross background
for seven or more generations. This advanced intercross back-
ground was intended to be similar to the approximate 50% B6
and 50% C3H genetic background of Ts65Dn mice. It may be that
residual background 129 alleles on the normal mouse chromo-
some 16 (not carrying the null Dyrk1a allele) cause the disparate
craniofacial and airway volume phenotypes observed in the tri-
somic and euploid offspring from the (Ts65Dn  Dyrk1aþ/)
matings. A possible explanation for the larger Ts65Dn cranial
vault in the Ts65Dn versus euploid and Ts65Dn versus
Ts65Dn,Dyrk1aþ/ comparisons is that a residual background
129 allele on chromosome 16 is interacting with B6 or C3H al-
leles possibly indicating the interactive effects of heterotrisomy
(54). Alternatively, an unknown epigenetic influence from the
Dyrk1aþ/ fathers may also have caused the differences in air-
way volume and craniofacial abnormalities seen between
Ts65Dn and euploid mice from the (Ts65Dn  Dyrk1aþ/) mat-
ings and mice treated with PBS. These hypotheses should be
tested in offspring from additional matings of (Ts65Dn 
Dyrk1aþ/) mice with a similar genetic background.
Supplements containing EGCG have been shown to improve
some cognitive and skeletal DS phenotypes in adult mice (33,
46). As the development of the face and brain is highly related
(55–57), embryonic EGCG treatment may also alter brain mor-
phology, which influences overall cranial vault shape during
morphogenesis and growth (57). The reduction in neurocranial
shape in Ts65Dn mice has been shown to correlate with the
characteristic flattened occiput found in humans with DS. This
region of the neurocranium overlies the cerebellum, which has
reduced volume in both Ts65Dn mice and individuals with DS
Figure 7. Craniofacial measurements of 6-week-old Ts65Dn and euploid mice
with or without EGCG treatment or Dyrk1a genetic reduction. Linear distances
that significantly differ by confidence interval testing (a¼0.10) from two-sample
EDMA comparisons of mouse cohorts are shown on lateral, superior and inferior
views of the mouse cranium and superior and lateral views of the mandible.
Linear distances that were significantly smaller or larger are depicted for each
comparison as dashed or solid lines. (A) EuploidþPBS compared with
Ts65DnþPBS: significant cranial base differences were found that include ante-
rioposterior dimensions of the palatine, basisphenoid and occipital bones.
Numerous rostrocaudal, mediolateral and superioinferior differences were
found across the face that include the nasal, premaxillae and maxillae bones.
Many height, width and length measurements of the mandible significantly dif-
fered. Several anterioposterior, mediolateral and superioinferior measures of
the cranial vault were also significant. (B) Euploidþ PBS compared with
Ts65DnþEGCG: significant cranial base differences were found that include
anterioposterior dimensions of the basisphenoid and occipital bones. Numerous
length, width and height significant differences were found across the face that
include the nasal, premaxillae and maxillae bones. Many anterioposterior,
mediolateral and superioinferior measurements of the mandible significantly
differed. Mediolateral differences in skull width were localized to the anterior
portion of the cranial vault including the zygomatic arches and frontal bone and
to the posterior cranial vault including the parietal bones. (C) Ts65DnþEGCG
compared with Ts65DnþPBS: significant superioinferior and mediolateral facial
differences including the premaxillae and nasal bones and significant cranial
vault width differences localized to the interparietal bone were smaller, whereas
a mandibular measure of incisor height was larger in Ts65Dnþ EGCG relative to
Ts65DnþPBS mice. (D) EuploidþEGCG compared with euploidþPBS: differ-
ences were found across the craniofacial skeleton and localized to the nasal,
premaxillae, maxillae, frontal, parietal, interparietal, occipital, basisphenoid
and mandibular bones. (E) Euploid compared with Ts65Dn: significant differ-
ences were present along the rostrocaudal and mediolateral axes of the face in-
cluding the malar process and the nasal, premaxillae and maxillae bones.
Numerous significant differences were present across the cranial vault along
the mediolateral and anterioposterior axes including the frontal, parietal and
interparietal bones. There were significant anterioposterior differences in con-
dylar process and coronoid process depth and significant mediolateral differ-
ences in mandibular width. (F) Euploid compared with Ts65Dn,Dyrk1aþ/:
significant facial aspects along the superioinferior–rostrocaudal dimensions in-
cluding the maxillae bones were larger in euploid mice, whereas significant cra-
nial vault dimensions along the anterioposterior and mediolateral axes
including the parietal and interparietal bones and a significant mandibular mea-
sure of incisor height were smaller in euploid relative to Ts65Dn,Dykr1aþ/mice.
(G) Ts65Dn,Dyrk1aþ/ compared with Ts65Dn: significant mediolateral differ-
ences in palatine bone width were found. One superioinferior–rostrocaudal fa-
cial measure of the maxillary bone significantly differed between samples. A
measure of incisor width was significant. There were numerous significant dif-
ferences in mediolateral and anterioposterior cranial vault dimensions crossing
the zygomatic, frontal, parietal, interparietal and squamosal bones. (H) Euploid
compared with euploid,Dyrk1aþ/: significant facial dimensions along the supe-
rioinferior and rostrocaudal dimensions including the premaxillae and maxillae
bones were larger, whereas a mandibular measure of incisor width was smaller
in euploid relative to euploid,Dyrk1aþ/mice.
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(7). Future studies will need to test the hypothesis that mice
with normalized cranial vault and other cranial structures may
also demonstrate a correlation in improved cognitive function.
Previous research has shown that relative to euploid mice,
Ts65Dn mice exhibit numerous differences across the craniofacial
complex including increased cranial vault width (i.e. brachyceph-
aly) and a generalized reduction in linear dimensions across
much of the skull including the face, mandible and dimensions of
the cranial vault length (7). Previous investigations of adult
Ts65Dn mice aged 4–7 months found brachycephaly in the ante-
rior andmiddle portions (near bregma) of the cranial vault (frontal
and parietal bones) (7), but the current investigation of 6-week-old
Ts65Dn mice only found increased width for some measures of
the anterior vault (frontal and zygomatic bones). Brachycephaly
was not reported in P0 Ts65Dn mice (14); thus, it seems likely that
brachycephaly is only beginning to develop in 6-week-old mice
and becomes fully developed in older Ts65Dn adult mice.
Euploid mice prenatally treated with EGCG exhibited numer-
ous craniofacial differences affecting practically all craniofacial
bones relative to euploid mice receiving PBS. The great majority
of significant differences was larger in the euploidþEGCG mice,
suggesting that EGCG treatment increased overall skull size rel-
ative to untreated euploid mice. This result also underscores
the important, but complicated role Dyrk1a plays in early osteo-
morphogenetic developmental events and subsequent craniofa-
cial growth. We have shown that the uterine environment of
the trisomic mother does not influence gross differences in
non-trisomic offspring (58) and therefore these results may
have implications in treating non-trisomic offspring with EGCG.
It is possible that trisomic Dyrk1a expression only alters cra-
niofacial and other precursors to specific DS-related phenotypes
in a temporally and spatially specific manner. Our data suggest
that an acute treatment of EGCG around the time of the NCC
deficit in the trisomic PA1 affects embryonic craniofacial
Table 1. Percentage of significant differences in cranial structures of 6-week-old Ts65Dn and euploid mice with or without EGCG treatment or
Dyrk1a dosage reduction
Comparison Percentage of significant differences (Significantly different distances/total distances measured)
Cranial base Cranial face Mandible Cranial vault
Ts65Dn þ PBS versus euploid þ PBS 19 (4/21) 32 (21/66) 52 (34/66) 22 (17/78)
Ts65Dn þ EGCG versus euploid þ PBS 14 (3/21) 26 (17/66) 53 (35/66) 5 (4/78)
Ts65Dn þ EGCG versus Ts65Dn þ PBS 0 (0/21) 5 (3/66) 3 (2/66) 3 (2/78)
Euploid þ EGCG versus euploid þ PBS 67 (14/21) 80 (53/66) 79 (52/66) 32 (25/78)
Ts65Dn versus euploid 0 (0/21) 8 (5/66) 3 (2/66) 17 (13/78)
Ts65Dn,Dyrk1aþ/ versus euploid 0 (0/21) 5 (3/66) 3 (2/66) 5 (4/78)
Ts65Dn,Dyrk1aþ/ versus Ts65Dn 10 (2/21) 3 (2/66) 5 (3/66) 12 (9/78)
Euploid,Dyrk1aþ/ versus euploid 0 (0/21) 6 (4/66) 2 (1/66) 0 (0/78)
Table 2. Body weights and nasopharyngeal airway volumes of 6-week-old Ts65Dn and euploid mice with or without EGCG treatment or Dyrk1a
dosage reduction
Genotype/treatment Mean 6-week weight in grams (SEM) [N] Mean airway volume in mm3 (SEM) [N]
Ts65Dn þ PBS 20.4 (0.85)a,b 8.7 (1.76)
[6] [5]
Ts65Dn þ EGCG 18.1 (0.73) 7.8 (0.93)
[5] [7]
Euploid þ PBS 23.3 (1.08)c 7.3 (1.31)
[5] [5]
Euploid þ EGCG 20.5 (0.57) 8.7 (1.99)
[7] [7]
Ts65Dn 19.7 (0.83)d,e 11.4 (0.78)f
[7] [8]
Ts65Dn,Dyrk1aþ/ 21.3 (0.45) 9.2 (0.94)
[12] [12]
Euploid 24.7 (0.37)g 13.0 (1.04)h
[14] [13]
Euploid, Dyrk1aþ/ 20.2 (1.57) 8.9 (2.53)
[3] [7]
Data reported as mean6 (SEM).
aP<0.05 when compared with euploidþPBS.
bP<0.001 when compared with Ts65DnþEGCG.
cP< 0.05 when compared with euploidþEGCG.
dP< 0.05 when compared with euploid.
eP<0.05 when compared with Ts65Dn,Dyrk1aþ/.
fP¼0.06 when compared with Ts65Dn,Dyrk1aþ/.
gP<0.001 when compared with euploid,Dyrk1aþ/.
hP<0.05 when compared with euploid,Dyrk1aþ/.
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precursors and structure of the adult cranial vault. Reducing tri-
somic Dyrk1a copy number did not correct embryonic Ts65Dn
appendicular skeletal development (46), but did significantly
correct adult skeletal phenotypes in the femur (29). In a similar
manner, upregulating the Shh pathway throughout develop-
ment did not correct Ts65Dn craniofacial differences but did
have some effect on cognitive phenotypes (59,60). Reduction of
the trisomic gene Ets2 to normal copy number in an otherwise
trisomic mouse also had minimal effect on correcting DS-
related craniofacial abnormalities (38). Temporally specific reg-
ulation of Dyrk1a or other genetic pathways may be important
to correct craniofacial and other DS-related phenotypes.
Because Ts21 can be detected prenatally, it is possible that
prenatal treatments could lead to corrections of DS phenotypes
(61,62). Many DS craniofacial and neurological processes are ini-
tiated or completed before birth, and a window for prenatal
treatment and permanent correction of DS-related phenotypes
may exist. A number of studies have examined prenatal treat-
ments of DS phenotypes and have mostly concentrated on cog-
nitive impairments [reviewed in (62)]. The use of prenatal
supplements to correct DS phenotypes needs to be further stud-
ied in animal models, including investigations of treatment tim-
ing and dosage, and precise quantification of phenotypes before
clinical trials in humans are proposed.
Materials and Methods
Generation and genotyping of mice and embryos
Female B6EiC3 Sn a/A-TS(1716)65Dn (Ts65Dn), B6CBA-Tg(Wnt1-
lacZ)206Amc/J (Wnt1-LacZ) and male B6C3F1 mice were
obtained from The Jackson Laboratory (Bar Harbor, ME). C57BL/
6-129/Ola Dyrk1a heterozygous mutant mice (Dyrk1aþ/) were
obtained from Dr Mariona Arbones (Institut de Recerca
Oncologica, Barcelona, Spain) (44,53). C57BL/6-129/Ola Dyrk1aþ/
mice were backcrossed to B6C3F1 mice for7 generations to
parallel the genetic background of Ts65Dn mice. All mice were
bred at Indiana University–Purdue University Indianapolis
(IUPUI) to produce the offspring needed for this study. Female
Ts65Dn mice were bred with Wnt1-LacZ or B6C3F1 males for
embryonic studies. Females were checked for vaginal plugs the
morning after mating to ascertain copulation. Noon on the day
of the plug was established as embryonic day 0.5 (E0.5) for de-
veloping embryos. Embryos were dissected from pregnant fe-
males and were assessed for developmental stage by somite
number. For E9.5 embryos (21–24 somites), pregnant mothers
were euthanized between 10 am and 12 pm 9 days after the
plug was visualized. For E9.25 embryos (15–18 somites), embryos
were dissected at 6 am 9 days after the plug was observed. For
E13.5 embryos, embryos were dissected at noon 13 days after
the plug was observed. Dissected E9.25, E9.5 and E13.5 embryos
were then fixed for histological analysis or PA1 and NT tissues
were isolated for further investigation. Mice and embryos uti-
lized for this study were genotyped by PCR (44,63) or fluores-
cence in situ hybridization (FISH) (64) as described. All animal
use and protocols were approved by the IUPUI School of Science
Institutional Animal Care and Use Committee (IACUC).
RNA isolation
The PA1 and NT of E9.5 or E9.25 embryos were dissected from
the embryos in an RNase free environment using 30 gauge nee-
dles. Structures dissected were specified by a cut matching the
line of the body for the PA1 and above the otic vesicle but below
the midbrain for the NT. RNA was extracted using the PureLink
RNA Micro Kit (Invitrogen, Carlsbad, CA) according to the manu-
facturer, and RNA concentration was assessed using the
Nanodrop ND-1000 (Thermo Scientific, Waltham, MA).
Immunohistochemistry for Nfat expression
E9.5 and E13.5 embryos for immunohistochemistry were fixed
in 4% paraformaldehyde, 5% sucrose in 0.1 M phosphate buffer
pH 7.4 for 4 h and infiltrated overnight with 20% sucrose in
phosphate buffer for cryo-embedding. Sections of E9.5 and E13.5
Ts65Dn and euploid embryos were permeabilized in 1 PBS
with 0.5% triton X-100, washed in 1 PBS with 5% SDS for anti-
gen retrieval, blocked with 10% donkey serum in PBS with 0.2%
Triton X-100 for 1 h, and treated with rabbit polyclonal Nfatc1
(sc-13033, dilution 1:20, SCBT) or goat polyclonal Nfatc2 (CSC-
1151, dilution 1:20, SCBT) diluted in blocking buffer overnight in
a humidified chamber at 4 C. Sections were washed and incu-
bated with secondary antibody [Alexaflour 594 donkey anti-
rabbit IgG (Invitrogen A21207), 1:750 and Alexafluor 488 donkey
anti-goat IgG (Invitrogen A-11055), 1:750] for 1 h at room tem-
perature and treated with Prolong gold DAPI antifade
(Invitrogen, P36935), coverslipped and sealed with nail polish.
Sections were examined for the nuclear localization of Nfatc1
(Nfatc1nuc) in the PA1 (E9.5) or Nfatc1 and Nfatc2 in Meckel’s car-
tilage (E13.5) using an Olympus FV-111-MPE confocal multipho-
ton microscope (Olympus, Center Valley, PA). Colocalization of
Nfatc1/2 and DAPI in the nuclei was analyzed using Image J soft-
ware (National Institute of Health, Bethesda, MD) utilizing
quantitative co-localization methodology (46,65).
Cell culture of trisomic and euploid embryonic cells
For cell proliferation and migration, the E9.5 PA1 and NT were
removed as described above and placed into 0.025% trypsin/
0.1% collagenase/Dulbecco’s phosphate-buffered saline (DPBS)
for 4 min at 37 C. Cells were triturated 10 times per sample
after incubation and then spun down at 9,280 g for 6min.
The supernatant was extracted from each tube and cells were
resuspended in 50 ml of MCDM (66). Resuspended cells were
plated on fibronectin-coated 96-well plates (Becton, Dickinson
and Company, Franklin Lakes, NJ) (proliferation assays) or
fibronectin-coated coverslips (migration assays). Cells were
incubated at 5% CO2 and 37 C in MCDM until confluence (12–
24 h, depending on genotype and tissue). During migration as-
says, media changes occurred daily until assays were
completed.
Proliferation assay for trisomic and euploid
craniofacial precursors
Cells derived from E9.5 PA1 and NT tissues were treated with
trypsin/collagenase/DPBS and grown on the 48-well plate for
24 h, then were quantified for cell titer using a hemacytometer.
For proliferation assays, cells were grown to confluency on 96-
well plates, transferred to 48-well plates, quantified, and
replated on new wells at a density of 1  104. From each sam-
ple consisting of suspended cells and 200 ml MCDM, 10 ml was re-
moved for quantification. For each cell titer, three counts were
taken on a hemocytometer and averaged to obtain a cell titer
per 4  103 mm2.
Cells were allowed to grow on the plate for 8 h and then were
treated with DMSO (Fair Lawn, NJ), Epigallocatechin-3-gallate
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(EGCG) (Sigma, St. Louis, MO) in DMSO or harmine (Sigma), an ad-
ditional inhibitor of Dyrk1a activity, in DMSO for 4 h. EGCG treat-
ments included doses of 10, 25 and 100 mM in DMSO and harmine
treatments included doses of 1 and 10 mM in DMSO. The media
was replaced and cells were incubated with MCDM for 4 h. Cell
Titer 96 AQueous One Solution Reagent (Promega, Madison, WI)
was added to each well and one control well with media and in-
cubated for 4 h. Proliferation was assessed using a spectropho-
tometer at 490nm and plotted on a standard curve to determine
the number of cells in each well. Proliferation of trisomic and eu-
ploid tissues was compared within the cell assay to determine
fold changes of proliferation for each trisomic sample relative to
euploid samples.
Migration assay of trisomic and euploid embryonic cells
Cells were placed on fibronectin-coated coverslips and incubated
at 5% CO2 and 37 C for 24 h in MCDM or until confluent, and then
the scratch assay was performed as described (67) by creating a di-
agonal scratch across the cell layer on the coverslip. Media was
changed to remove debris from the scratch, and cells were treated
for 4 h with DMSO, EGCG in DMSO or harmine in DMSO at concen-
trations described above. Migration was quantified 0, 24, 48 and
72 h after the scratch was made. MCDM was changed daily with
care taken to avoid disturbing the cells. Using Image J, the number
of cells in the scratch was quantified and recorded as follows: each
scratch was outlined to ensure conformity among scratch width
before proceeding to quantification. Any images with inconsistent
scratch widths were not utilized in this analysis. Using the count-
ing tool, the number of cells within each scratch not touching the
borders outlining the scratch was quantified for three images per
culture. An average of these three numbers was then used as ami-
gration count for that sample. Migration rates were established as
the number of cells fully migrated into the scratch divided by the
length of time since the scratch test was initiated in hours.
Trisomic migration rates were then compared with euploid migra-
tion rates of the same tissue and culture group.
Quantitative PCR to assess differential RNA
expression in E9.5 PA1
RNA was converted to cDNA using the TaqMan Reverse
Transcription Reagents (Applied Biosystems, Carlsbad, CA). Using
this cDNA, master mixes were created for the reference gene (ac-
tin, Ev1) and target genes using TaqMan Gene Expression Master
Mix (Applied Biosystems). Samples were analyzed in duplicate us-
ing the AB 7300 Real Time PCR System (Applied Biosystems).
Crossing point (Cp) values from each duplicate trisomic sample
were then averaged and divided by the average Cp value of the
two euploid samples as performed by the 7300 System Software
(Applied Biosystems). To determine a fold change, Cp values were
subjected to the 2DDCp formula as described (68). Relative quanti-
fication was performed on Ts65Dn and euploid littermate PA1
from both treated and untreated embryos. Expression was quanti-
fied for Ev1 (actin, housekeeping gene), Dyrk1a, Rcan1, Shh, Gli1,
Ptch1 and Ets2 probes (Applied Biosystems).
In vivo assessment of EGCG treatment during
embryonic stages
For mice treated on embryonic (gestational) days 7 and 8 (E7
and E8), plugged female mice (Ts65Dn  Wnt1LacZ matings)
were given 200 mg/kg EGCG dissolved in PBS or PBS alone twice
daily at least 6 h apart by oral gavage using a 22 gauge feeding
needle (69). 200 mg/kg EGCG oral gavage using a 15 mg/ml solu-
tion in a 30 g mouse results in the delivery of 13 mmol EGCG.
Mice were given water ad libitum before and after the oral ga-
vage. For mice treated from E0 to E9 (Ts65Dn or euploid 
B6C3F1 matings), pregnant females were given water or 0.124 g/
ml EGCG in 25 ml water in feeding tubes after the plug was de-
tected at E0.5, without other liquid, and allowed to drink ad libi-
tum. EGCG or water volume was measured and changed every
48 h. Mice were strictly monitored for general health, assessed
by daily weight changes, locomotor activity in the cage, and re-
sponse to handling over the 2-day period of treatment before
euthanizing. On day 9 after the plug was found, females were
euthanized and E9.5 embryos dissected. Embryos were pro-
cessed, fixed and sectioned as previously described (18).
Stereological analysis of craniofacial precursors
Unbiased stereology (70) was used to quantify embryo and PA1
size and cell number. Systematic random sampling was used to
quantify the number of cells in the PA1 and Calvalieri-point
counting was utilized from volumetric measurements.
Embryonic volume was assessed on every fourth section and
PA1 volume and cell number were assessed sampling every
third section containing PA1. Embryo volume was assessed
with a frame area of 25 mm2, 10 mm frame height, 2 mm guard
height, 200 mm from spacing, 8000 mm2 area per point and sam-
pling from the top of the section. PA1 quantification was per-
formed using dissectors spaced at intervals of 60 mm with
dimensions of 150 mm2 area and 8 mm depth with a 2 mm guard
height. Average coefficient of error for all volumes and cell
counts was0.10. Statistical differences were determined using
a one-tailed Student’s t-test.
Assessment of embryonic EGCG treatment or Dyrk1a
reduction on adult mice
Pregnant Ts65Dn mice were given 200mg/kg EGCG twice daily
by gavage on E7 and E8 as described above. Mice were housed
until parturition, genotyped and offspring weaned after 21 days.
Four types of mice were analyzed: Ts65Dn (n¼ 6),
Ts65DnþEGCG (n¼ 7), euploid (n¼ 5) and euploidþEGCG (n¼ 7).
Ts65Dn mice were bred to Dyrk1a heterozygous knockout mice
(44). Offspring from the (Ts65Dn  Dyrk1aþ/) cross were geno-
typed for trisomy as well as the Dyrk1a knockout as described
(44,63). Four types of mice from this breeding scheme were ana-
lyzed: Ts65Dn (n¼ 8), Ts65Dn,Dyrk1aþ/ (n¼ 13), euploid (n¼ 14)
and euploid,Dyrk1aþ/ (n¼ 7). At the age of 6 weeks, multiple
skulls/heads from these offspring were imaged at the same
time using high resolution micro-computed tomography (mCT;
35 mm resolution) at the Indiana University School of Medicine.
The images were segmented into separate heads and 3D bony
isosurfaces of mCT image data were visualized and measured
using Dolphin software (v11.5; Chatsworth, CA). Anatomical
landmark coordinates from the craniofacial skeleton (n¼ 44)
were identified (Supplementary Material, Fig. S7) and their x, y
and z coordinates recorded for morphometric analysis.
Additionally, nasopharynx airway volumes (mm3) were mea-
sured from mCT images using Dolphin software (Supplementary
Material, Fig. S8). Anatomical landmark coordinate values and
nasopharynx airway volumes were measured on two separate
occasions with at least 24 h in between measurement sessions
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to avoid memory bias, inspected for gross errors and then aver-
aged to minimize potential effects of measurement error.
Differences in skull form among samples were analyzed us-
ing 3D landmark coordinate data and Euclidean distance matrix
analysis (EDMA) as previously reported (52). EDMA converts 3D
landmark coordinate data into an equivalent description of
form called a form matrix, which consists of all unique linear
distances among landmarks. Morphological differences be-
tween samples were statistically compared using a nonpara-
metric bootstrap (10 000 resamples) and confidence interval
testing (a¼ 0.10) to determine local differences in craniofacial
form. The null hypothesis was that average linear distance
measures between the samples are the same (41,42). The per-
centage of significant differences in summary statistics was cal-
culated by counting the number of significant linear distances
in a particular craniofacial region (e.g. cranial vault, face, base
or mandible) and dividing it by the total number of unique lin-
ear distances for that particular region [i.e. the number of linear
distances that could have potentially been significantly differ-
ent, which is calculated using nðn1Þn , where n is equal to the
number of landmarks measured in the region of interest] (44) to
assess global region by region differences in patterns of varia-
tion across multiple two-sample EDMA form comparisons
(4,52). Nasopharyngeal airway volumetric values were com-
pared between samples using independent t-tests.
Supplementary Material
Supplementary Material is available at HMG online.
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